The Claim
A serum TSAb level exceeding 2000% at the time of anti-thyroid drug discontinuation in patients with Graves' disease is associated with a high likelihood of disease relapse.
What the research says
Challenges is higher
Challenge is ahead, but a single strong supporting study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
In patients with Graves' disease who stop taking anti-thyroid drugs, a blood test showing TSAb levels above 2000% is linked to a higher chance of the disease returning.
See the scientific wording
In patients with Graves' disease, a serum TSAb level exceeding 2000% at the time of anti-thyroid drug discontinuation is associated with a high likelihood of relapse, suggesting it may serve as a threshold marker for identifying high-risk individuals.
When thyroid-stimulating antibodies remain very high, they keep forcing the thyroid gland to produce too much hormone, which prevents the immune system from calming down. This keeps the immune attack going, so the disease comes back after treatment stops.
What the research says
1 studyThe study found that even when people with Graves' disease had very high levels of the antibody linked to relapse, many still stayed healthy after stopping medication — so a single high number like 2000% can't reliably tell who will get sick again.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.